NCT05992428View on ClinicalTrials.gov

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

November 7, 2023

Study Completion Date

December 5, 2023

Conditions
Healthy
Interventions
DRUG

DA-8010 5mg

\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg

DRUG

Paroxetine 20mg

\[Part 1\] DA-8010 5mg + Paroxetine 20mg

DRUG

Mirabegron 50mg

\[Part 2\] DA-8010 5mg + Mirabegron 50mg

Trial Locations (1)

Unknown

Seoul National University Hospital, Soeul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY